Abstract
AbstractDuring the COVID-19 pandemic, breast and ovarian cancer survivors experienced more anxiety and depression than before the pandemic. Studies have not investigated the similarities of this trend among BRCA1/2-positive women who are considered high risk for these cancers. The current study examines the impact of COVID-19 experiences on anxiety and depression in a sample of BRCA1/2-positive women in the U.S. 211 BRCA1/2-positive women from medically underserved backgrounds completed an online survey. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression for associations between COVID-19 experiences and self-reported anxiety and depression stratified by demographic factors. Overall, women who reported COVID-19 stigma or discrimination (aOR, 5.14, 95% CI [1.55, 17.0]) experienced significantly more depressive symptoms than women who did not report this experience. Racial/ethnic minority women caring for someone at home during COVID-19 were 3.70 times more likely (95% CI [1.01, 13.5]) to report high anxiety while non-Hispanic white women were less likely (aOR, 0.34, 95% CI [0.09, 1.30], p interaction = 0.011). To date, this is the first study to analyze anxiety and depression considering several COVID-19 predictors among BRCA1/2-positive women. Our findings can be used to inform future research and advise COVID-19-related mental health resources specific to these women.
Funder
National Cancer Institute
Johns Hopkins Ho-Chiang Yang Memorial Faculty Award
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. American Cancer Society (ACS). Family Cancer Syndromes. https://www.cancer.org/cancer/cancer-causes/genetics/family-cancer-syndromes.html (2020).
2. Godet, I. & Gilkes, D. M. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integrat. Cancer Sci. Technol. 4, 10 (2017).
3. Mersch, J. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121, 269–275. https://doi.org/10.1002/cncr.29357 (2015).
4. Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA https://doi.org/10.1001/jama.2017.7112 (2017).
5. Haque, R. et al. Survival outcomes in BRCA1 or BRCA2 mutation carriers and the influence of triple-negative breast cancer subtype. Permanente J. 22, 170–197. https://doi.org/10.7812/TPP/17-197 (2018).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献